<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384770</url>
  </required_header>
  <id_info>
    <org_study_id>20-000328</org_study_id>
    <secondary_id>NCI-2020-02911</secondary_id>
    <nct_id>NCT04384770</nct_id>
  </id_info>
  <brief_title>CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study</brief_title>
  <official_title>Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (Mirage): A Phase III Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies compares CT-guided stereotactic body radiation therapy and&#xD;
      MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer.&#xD;
      Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the&#xD;
      cancer within the body with the delivery of therapeutic radiation doses produced on a linear&#xD;
      accelerator machine. Imaging modalities for image-guided SBRT can be either computed&#xD;
      tomography imaging (CT), magnetic resonance imaging (MRI), or a combination of the two. This&#xD;
      research is being done to help determine whether there are benefits to MRI-guidance over&#xD;
      CT-guidance in patients who are receiving the same radiation dose by SBRT to treat prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether (MRI)-guided stereotactic body radiotherapy (SBRT) improves acute&#xD;
      physician-scored genitourinary (GU) toxicity when compared with standard computed tomography&#xD;
      (CT)-guided SBRT for prostate cancer (PCa).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether there are differences in acute grade &gt;= 2 gastrointestinal (GI)&#xD;
      toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version&#xD;
      4.03 scale, following MRI-guided SBRT versus CT-guided SBRT.&#xD;
&#xD;
      II. To determine whether there are differences in 5-year cumulative incidences of late grade&#xD;
      &gt;= 2 GU and GI physician-reported toxicity, following MRI-guided SBRT versus CT-guided SBRT.&#xD;
&#xD;
      III. To quantify the temporal changes in patient-reported quality of life (QOL) outcomes, as&#xD;
      assessed by the Expanded Prostate Cancer Index-26 (EPIC-26), International Prostate Symptom&#xD;
      Scores (IPSS), and Sexual Health Inventory for Men (SHIM) QOL indices, following MRI-guided&#xD;
      SBRT.&#xD;
&#xD;
      IV. To determine whether there are differences in 5-year biochemical recurrence-free survival&#xD;
      (BCRFS) following MRI-guided SBRT.&#xD;
&#xD;
      V. To observe the proportion of SBRT fractions for which on-line adaptive radiotherapy is&#xD;
      required due to changes in organ-at-risk anatomy.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      GROUP II: Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 1 year,&#xD;
      every 6 months for 4 years, and then yearly thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute grade &gt;= 2 genitourinary (GU) physician-reported toxicity</measure>
    <time_frame>90 days after stereotactic body radiation therapy (SBRT)</time_frame>
    <description>Will be assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute grade &gt;= 2 gastrointestinal (GI) toxicity</measure>
    <time_frame>90 days after SBRT</time_frame>
    <description>Will be assessed by the CTCAE version 4.03 scale and rates will be reported descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of late grade &gt;= 2 GU toxicity</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed by the CTCAE version 4.03 scale and analyzed using a cumulative incidence framework.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidences of late grade &gt;= 2 GI toxicity</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed by the CTCAE version 4.03 scale and analyzed using a cumulative incidence framework.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life (QOL) outcomes</measure>
    <time_frame>Up 5 years</time_frame>
    <description>For the Expanded Prostate Cancer Index- 26 (EPIC-26) instrument, these will be represented by changes from baseline in the urinary incontinence, urinary obstruction, bowel, sexual function, and hormone/vitality domains. Changes will be analyzed with respect to whether they represent minimally important differences. For the International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) instruments, the numerical change from baseline, as well as the raw score at any given timepoint, will be extracted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical recurrence-free survival (BCRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method as well as descriptively (mean, standard deviation, median, first and third quartiles, minimum, maximum)., with biochemical recurrence (BCR) defined as serum PSA levels that are 2 ng/mL higher than the nadir PSA achieved after SBRT.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">113</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Group I (CT-SBRT)</arm_group_label>
    <description>Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (MRI-SBRT)</arm_group_label>
    <description>Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT-guided Stereotactic Body Radiation Therapy</intervention_name>
    <description>Undergo CT-guided SBRT</description>
    <arm_group_label>Group I (CT-SBRT)</arm_group_label>
    <other_name>Computed Tomography-Guided Stereotactic Body Radiation Therapy</other_name>
    <other_name>CT-guided SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI-guided Stereotactic Body Radiation Therapy</intervention_name>
    <description>Undergo MRI-guided SBRT</description>
    <arm_group_label>Group II (MRI-SBRT)</arm_group_label>
    <other_name>Magnetic Resonance Imaging-guided Stereotactic Body Radiation Therapy</other_name>
    <other_name>MR-guided SBRT</other_name>
    <other_name>MRI-guided SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (CT-SBRT)</arm_group_label>
    <arm_group_label>Group II (MRI-SBRT)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving stereotactic body radiation therapy for the treatment of prostate cancer&#xD;
        at the University of California, Los Angeles&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, clinical localized adenocarcinoma of the prostate&#xD;
&#xD;
          -  No evidence of disease beyond the prostate and/or seminal vesicles (i.e., no&#xD;
             suspicious pelvic lymph nodes or presence of metastatic disease outside the pelvis)&#xD;
&#xD;
          -  Staging workup as recommended by the National Comprehensive Cancer Network (NCCN) on&#xD;
             the basis of risk grouping:&#xD;
&#xD;
               -  Low risk: No staging workup required&#xD;
&#xD;
               -  Favorable intermediate-risk: CT abdomen/pelvis if Memorial Sloan Kettering Cancer&#xD;
                  Center (MSKCC) nomogram predicts &gt;10% probability of lymph node involvement&#xD;
&#xD;
               -  Unfavorable intermediate-risk: technetium bone scan, CT abdomen/pelvis if MSKCC&#xD;
                  nomogram predicts &gt;10% probability of lymph node involvement&#xD;
&#xD;
               -  High-risk: technetium bone scan, CT abdomen/pelvis if MSKCC nomogram predicts&#xD;
                  &gt;10% probability of lymph node involvement&#xD;
&#xD;
               -  Advanced imaging studies (i.e. prostate-specific membrane antigen positron&#xD;
                  emission tomography [PSMA PET] and axumin scan) can supplant a bone scan if&#xD;
                  performed first&#xD;
&#xD;
          -  Ability to understand, and willingness to sign, the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with neuroendocrine or small cell carcinoma of the prostate&#xD;
&#xD;
          -  Patients with any evidence of distant metastases. Note, evidence of lymphadenopathy&#xD;
             below the level of the renal arteries can be deemed loco regional per the discretion&#xD;
             of the investigator&#xD;
&#xD;
          -  Prior cryosurgery, high intensity focused ultrasound (HIFU) or brachytherapy of the&#xD;
             prostate&#xD;
&#xD;
          -  Prior pelvic radiotherapy&#xD;
&#xD;
          -  History of Crohn's disease, ulcerative colitis, or ataxia telangiectasia&#xD;
&#xD;
          -  Contraindications to MRI, including:&#xD;
&#xD;
               -  Electronic devices such as pacemakers, defibrillators, deep brain stimulators,&#xD;
                  cochlear implants;&#xD;
&#xD;
               -  Metallic foreign body in the eye or aneurysm clips in the brain;&#xD;
&#xD;
               -  Severe claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Kishan</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

